Combined Prognostic Value of Preprocedural Protein–Energy Wasting and Inflammation Status for Amputation and/or Mortality after Lower-Extremity Revascularization in Hemodialysis Patients with Peripheral Arterial Disease
-
Published:2023-12-25
Issue:1
Volume:13
Page:126
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Kumada Yoshitaka1, Kawai Norikazu1, Ishida Narihiro1, Nakamura Yasuhito1, Takahashi Hiroshi2, Ohshima Satoru3, Ito Ryuta3, Izawa Hideo2ORCID, Murohara Toyoaki4, Ishii Hideki5ORCID
Affiliation:
1. Department of Cardiovascular Surgery, Matsunami General Hospital, Kasamatsu 501-6062, Japan 2. Department of Cardiology, Fujita Health University School of Medicine, Toyoake 470-1192, Japan 3. Department of Cardiology, Nagoya Kyoritsu Hospital, Nagoya 454-0933, Japan 4. Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan 5. Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan
Abstract
Protein–energy wasting is associated with inflammation and advanced atherosclerosis in hemodialysis patients. We enrolled 800 patients who had undergone successful lower-extremity revascularization, and we investigated the association among the Geriatric Nutritional Risk Index (GNRI) as a surrogate marker of protein–energy wasting, C-reactive protein (CRP), and their joint roles in predicting amputation and mortality. They were divided into lower, middle, and upper tertiles (T1, T2, and T3) according to GNRI and CRP levels, respectively. Regarding the results, the amputation-free survival rates over 8 years were 47.0%, 56.9%, and 69.5% in T1, T2, and T3 of the GNRI and 65.8%, 58.7%, and 33.2% for T1, T2, and T3 of CRP, respectively (p < 0.0001 for both). A reduced GNRI [adjusted hazard ratio (aHR) 1.78, 95% confidence interval (CI) 1.24–2.59, p = 0.0016 for T1 vs. T3] and elevated CRP (aHR 1.86, 95% CI 1.30–2.70, p = 0.0007 for T3 vs. T1) independently predicted amputation and/or mortality. When the two variables were combined, the risk was 3.77-fold higher (95% CI 1.97–7.69, p < 0.0001) in patients who occupied both T1 of the GNRI and T3 of CRP than in those who occupied both T3 of the GNRI and T1 of CRP. In conclusion, patients with preprocedurally decreased GNRI and elevated CRP levels frequently experienced amputation and mortality, and a combination of these two variables could more accurately stratify the risk.
Funder
Bayer Sumitomo Pharma PDR Pharma Biotronik Japan Abbott Japan Boston Scientific Japan Japan Lifeline Medtronic Japan Otsuka Novartis Eli Lilly Japan Nippon Boehringer Ingelheim Daiichi Sankyo Kowa Co., Ltd. MSD K.K. Mitsubishi Tanabe Pharma Co. Pfizer Japan Inc. Sanofi-aventis K.K. Takeda Pharmaceutical Co., Ltd. Department of Cardiology, Nagoya University Graduate School of Medicine Daiichi Sankyo Co., Ltd. Teijin Pharma Ltd. Astrazeneca Inc. Bristol-Myers Squibb Inc. Chugai Pharmaceutical Co., Ltd.
Reference39 articles.
1. GBD Chronic Kidney Disease Collaboration (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709–733. 2. GBD 2017 Causes of Death Collaborators (2018). Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 392, 1736–1788. 3. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016—40 for 195 countries and territories;Foreman;Lancet,2018 4. Prognostic Value of Chronic Kidney Disease Measures in Patients with Cardiac Disease;Mok;Circ. J.,2017 5. Novel “Predictor Patch” Method for Adding Predictors Using Estimates from Outside Datasets—A Proof-of-Concept Study Adding Kidney Measures to Cardiovascular Mortality Prediction;Matsushita;Circ. J.,2019
|
|